Clinton F. Stewart, PharmD
Clinton F. Stewart, PharmD

Clinton F. Stewart, PharmD

Member, St. Jude Faculty



BSPh – Auburn University
PharmD – University of Tennessee, Memphis, TN

Honors & Awards

  • 2012 Research Advisor Award, University of Tennessee Health Science Center, College of Graduate Health Sciences
  • 2009 Fellow, American Association of Pharmaceutical Scientists
  • 1994 Fellow, American College of Clinical Pharmacists

Research Interests

  • CNS and tumor penetration of novel agents used to treat pediatric CNS tumors in relevant mouse models
  • Pharmacokinetic and pharmacodynamic modeling and simulation to derive safe and effective anti-cancer drug regimens for infants and young children with brain tumors
  • Novel methods to optimize drug exposure in children with cancer (eg, pharmacokinetically guided dosing)

Improving Drug Therapy for Children with Brain Tumors

Selected Publications

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Robinson S, Turner D, Zindy F, Wang Y-D, Finkelstein D, Bihannic L, Puget S, Ayrault O, Li X-N, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF. Pemetrexed and gemcitabine as combination therapy for the treatment of group 3 medulloblastoma. Cancer Cell 25(4):516-529, 2014. (PMCID: 24684846).

Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panadiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar. Evaluation of amifostine for protection for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-Oncol 16(6):848-55, 2014. (PMCID: 24414535).

Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, Doz F, Ellison DW, Endersby R, Fisher PG, Hassall T, Heath JA, Hil HL, Jones DT, Junckerstorff R, Kellie S, Kool M, Kotecha RS, Lichter P, Laughton SJ, Lee S, McCowage G, Northcott PA, Olson JM, Packer RJ, Packer RJ, Pfister SM, Pietsch T, Pizer B, Pomeroy SL, Remke M, Robinson GW, Rutkowski S, Schoep T, Schoep T, Shelat AA, Stewart C, Sullivan M, Taylor MD, Wainwright B, Walwyn T, Weiss WA Williamson D, Gajjar A. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 127:189-201, 2014. (PMCID:PMC3895219).

Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci 57:41-7, 2014. (PMCID: 24269626).

Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 19:6305-12, 2013. (PMCID:PMC3856244).

Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. A molecular biology and Phase II trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium Study. J Neuro-Oncology 114:173-9, 2013. (PMCID: 23836190)

Yang JJ, Lim JY-S, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, Shuyu E, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-induced Ototoxicity in Children with Cancer. Clinical Pharmacol Therap 94:252-9, 2013. (PMCID:PMC3883563)

MacDonald TJ, Vezina G, Stewart CF, Turner D, Pierson CR, Chen L, Pollack IF, Gajjar A, Kieran MW. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-Oncology 15:1438-44, 2013. (PMCID:PMC3779033)

Broniscer A, Baker SD, Wetmore C, Pai Panadiker A, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clinical Cancer Research 19: 3050-3058, 2013. (PMCID:PMC3685168)

Roberts MS, Turner DC, Owens TS, Ramachandran A, Wetmore C, Throm SL, Stewart CF. Determination of crenolanib in human serum and cerebrospinal fluid by liquid-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). J Chrom B 292:1-5, 2013. (PMCID:PMC3665945).

Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. Pediatr Blood Cancer 60:627-632, 2013. (PMCID:PMC3573253).

Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, Hicks JK, Stewart CF, Kawedia JD, Ramsey LB, Liu C, Evans WE, Relling MV, Broeckel U. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Therap 92:360-5, 2012. (PMCID: PMC3516299)

Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer Nov 15;118(22):5663-70, 2012. (PMCID:PMC3413782)

Kasow KA, Stewart CF, Barfield RC, Wright NL, Li C, Srivastava DK, Leung W, Horwitz EM, Bowman LC, Handgretinger R, Hale GA. A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplant 47:1448-1454, 2012.

Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 118:4321-4330, 2012. (PMCID: 22252903)

McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez-Galindo C. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer 58:372-9, 2012. (PMCID: PMC3256281)

Bai F, Johnson J, Wang F, Yang L, Broniscer A, Stewart CF. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2561-6, 2011. (PMCID: PMC3162072)

Elmeliegy MA, Carcaboso AM, L Chow LM, Zhang ZM, Calabrese C, Throm SL, Wang F, Baker SJ,Stewart CF. Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci 100:4210-4214; 2011. (PMCID:PMC3750095)

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-99, 2011. (PMCID: PMC3172881)

Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol 29:4351-7, 2011. (PMCID: PMC3221519)

Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. A phase I/II trial of MK0752 in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 29:3529-3534, 2011. (PMCID: PMC3179253)

Zhang F, Throm SL, Murley LL, Miller LA, Zatechka DS, Guy RK, Kennedy R, Stewart CF. MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport. Biochem Pharmacol 82:24-24, 2011. (PMCID: PMC3108438)

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99, 2011. (PMCID: PMC3017236)

Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF. Whole-body physiologically-based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Disp 39:15-21, 2011. (PMCID: PMC3014266)

Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. Neuro Oncol 13:290-297, 2011. (PMCID: PMC3064605)

Last update: February 2014